Here, we presented an EGFRL858R/T790M/FGFR1 dual-inhibitor 15c, which can simultaneous inhibited the kinase activity of EGFRL858R/T790M and FGFR1 both in kinase assay and cell study, for the treatment of FGFR1-amplified EGFR-TKIs resistant lung cancers. This evidence concerns the gene FGFR1 and lung cancer.